A-share private fund research activity has been continuously rising recently.
Overall, electronics and pharmaceutical biology have become the two most closely watched sectors, with both billion-yuan private funds and small-to-medium private funds increasing their research efforts.
Data shows that in October, a total of 1,037 private fund institutions participated in research on A-share listed companies, conducting 5,310 research visits in total, covering 27 Shenwan primary industries and 463 individual stocks.
Among them, 58 billion-yuan private funds conducted 704 research visits in total, covering 277 individual stocks across all 27 industries.
Industry Distribution: Resources Concentrated in a Few Hot Sectors
From an industry distribution perspective, research resources were clearly concentrated in a few popular sectors.
During the month, 13 industries received 100 or more research visits, with four industries 鈥?electronics, pharmaceutical biology, power equipment, and machinery equipment 鈥?each exceeding 500 visits.
Specifically, the electronics industry ranked first with 986 research visits, covering 73 individual stocks; the pharmaceutical biology industry followed closely with 976 visits, covering 62 individual stocks; the power equipment industry received 548 visits, involving 35 individual stocks; and the machinery equipment industry also exceeded 500 visits, covering 52 individual stocks.
These four major industries together accounted for 3,039 research visits, representing 57.23% of the total research visits for the month.
Individual Stock Level: 183 Stocks Received Research from at Least 10 Private Fund Institutions
At the individual stock level, a total of 183 stocks received research from at least 10 private fund institutions.
The top ten stocks by research popularity, in order, are: Yuanjie Semiconductor Technology Co.,Ltd. (ASX: 688498), Victory Giant Technology(Huizhou) Co.,Ltd. (ASX: 300476), Mindray Medical, Hikvision, Jinpan Technology, Eoptolink Technology, United Imaging Healthcare, Centre Testing International, Shenzhen Everbest Machinery Industry, and Dongpeng Beverage.
It is worth noting that leading institutions showed particularly concentrated interest in popular individual stocks.
Among the institutions participating in research on Yuanjie Semiconductor Technology Co.,Ltd. (ASX: 688498), there were 12 billion-yuan private funds including Dunhe Asset Management, Gaoyi Asset Management, Greenwoods Asset Management, and Jiuqi Investment; Victory Giant Technology(Huizhou) Co.,Ltd. (ASX: 300476) attracted 11 billion-yuan private funds including Greenwoods Asset Management, Ridou Investment, Yaojinghe Private Fund, Chanlong Asset Management, Fusheng Asset Management, and Gaoyi Asset Management.
Institutional Activity: Small and Medium Private Funds Equally Active as Leading Institutions
From the perspective of institutional activity, small and medium private funds performed just as actively as leading institutions.
During the month, a total of 130 private funds conducted no fewer than 10 research visits, with the top ten institutions each exceeding 50 visits.
Among the billion-yuan private fund camp, in addition to Gaoyi Asset Management, Springs Capital and Juming Investment also ranked among the top ten institutions by research visits, conducting 63 and 54 visits respectively.
Breaking Down Leading Institutions' Research Preferences
Further breaking down the research preferences of leading institutions: Springs Capital covered 62 individual stocks during the month, including 27 in the pharmaceutical biology industry, with Huadong Medicine receiving 2 research visits; Juming Investment covered 54 individual stocks with a relatively balanced industry distribution, including 14 in electronics, 13 in power equipment, and 11 in pharmaceutical biology.
In addition, 9 other billion-yuan private funds conducted 20 or more research visits during the month, including Shanghai Ivy Private Fund, Yaojinghe Private Fund, Chongyang Investment, and Greenwoods Asset Management.
Among them, Chongyang Investment conducted 24 research visits covering 24 individual stocks, with 15 in the pharmaceutical biology industry; Greenwoods Asset Management also conducted 24 research visits covering 24 individual stocks, with 9 in the electronics industry.
Comments